Greg Yap
PartnerBio + Healthcare
Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo investments including Cartwheel, Clear Labs, Curie, Delfi, Encoded, Epiodyne, Genesis, H1, Koala, Ophelia, Particle, Pliant (PLRX), Riva, and Scribe. He has also been involved in Menlo’s investments in Benchling and Recursion (RXRX).
Previously, Greg was at Illumina Ventures as entrepreneur-in-residence, where he focused on new investments related to genomics. Prior to entering venture capital, Greg had 20 years of experience in senior executive and entrepreneurial roles in life science and digital health. He was CEO and co-founder of two startups: BlueLight Therapeutics (originally Biodesy), a structure-driven platform therapeutics company, and PyrAmes, a digital health remote monitoring company. At Roche Diagnostics/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million in revenue annually. Greg’s operating experience also includes roles as the first healthcare entrepreneur-in-residence at GE; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix, the microarray genomics pioneer; and consultant for McKinsey & Company.
Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton University and his MBA from Stanford University’s Graduate School of Business. He is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Greg is a Bay Area native and has lived in 11 cities in the area. Greg serves on the board of Outward Bound California and loves all manner of outdoor activities with his family, including backpacking and snowboarding. His favorite sport is basketball.
Supported by: Lauren Etienne, [email protected]
Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo investments including Cartwheel, Clear Labs, Curie, Delfi, Encoded, Epiodyne, Genesis, H1, Koala, Ophelia, Particle, Pliant (PLRX), Riva, and Scribe. He has also been involved in Menlo’s investments in Benchling and Recursion (RXRX).
Previously, Greg was at Illumina Ventures as entrepreneur-in-residence, where he focused on new investments related to genomics. Prior to entering venture capital, Greg had 20 years of experience in senior executive and entrepreneurial roles in life science and digital health. He was CEO and co-founder of two startups: BlueLight Therapeutics (originally Biodesy), a structure-driven platform therapeutics company, and PyrAmes, a digital health remote monitoring company. At Roche Diagnostics/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million in revenue annually. Greg’s operating experience also includes roles as the first healthcare entrepreneur-in-residence at GE; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix, the microarray genomics pioneer; and consultant for McKinsey & Company.
Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton University and his MBA from Stanford University’s Graduate School of Business. He is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Greg is a Bay Area native and has lived in 11 cities in the area. Greg serves on the board of Outward Bound California and loves all manner of outdoor activities with his family, including backpacking and snowboarding. His favorite sport is basketball.
Supported by: Lauren Etienne, [email protected]
Investments
Our Portfolio
Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.
Milestones
- 2012 → Founded
- 2019 → Partnered, Series C
Partner
Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.
Milestones
- 2019 → Founded
- 2019 → Partnered, Seed
Partner
Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.
Milestones
- 2014 → Founded
- 2019 → Partnered, Series C
Partner
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Milestones
- 2019 → Founded
- 2020 → Partnered, Series A
Partner
Ophelia is reinventing drug rehab by making evidence-based treatment private, affordable, and accessible via telemedicine.
Milestones
- 2019 → Founded
- 2021 → Partnered, Series A
Partner
NASDAQ: RXRX Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.
Milestones
- 2013 → Founded
- 2017 → Partnered, Series B
- 2021 → IPO; NASDAQ: RXRX
Partner
Riva Health provides a digital cardiology platform designed to give patients a comprehensive, equitable, and accessible way to manage hypertension and heart disease.
Milestones
- 2013 → Founded
- 2017 → Incubated by Menlo Labs
- 2019 → Seed
- 2021 → Series A
Partner
Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.
Milestones
- 2015 → IPO
Partner
Cartwheel is a tech-enabled provider for youth mental health services, helping schools and families tackle the student mental health crisis.
Milestones
- 2022 → Founded
- 2023 → Partnered, Series A
Partner
Clear Labs offers the only automated next-generation sequencing platform for applications including COVID diagnostics and food safety testing.
Milestones
- 2014 → Founded
- 2018 → Partnered, Series B
Partner
Cofactor Genomics is a biotech company whose mission is to enable drug development, medical research, and personalized medicine using RNA-based information and technologies.
Milestones
- 2008 → Founded
- 2017 → Partnered, Series A
Partner
Earli’s mission is to make cancer a benign experience, by catching and curing it early.
Milestones
- 2018 → Founded
- 2021 → Partnered, Series A
Partner
Epiodyne is developing breakthrough opioid medicines to manage pain and treat opioid use disorder (OUD) with minimal potential for addiction and safety risks.
Milestones
- 2016 → Founded
- 2018 → Partnered, Series A
Partner
Koala is a modern pet healthcare provider with a mail order pharmacy offering for pet medications.
Milestones
- 2021 → Founded
- 2022 → Partnered, Series A
Partner
Particle Health is an API designed for healthcare innovators that gives access to vital medical data.
Milestones
- 2017 → Founded
- 2020 → Partnered, Series A
Partner
Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Milestones
- 2015 → Founded
- 2018 → Partnered, Series B
- 2020 → IPO; NASDAQ: PLRX
Partner
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying causes of genetic disorders.
Milestones
- 2018 → Founded
- 2021 → Partnered, Series B
Partner
Led by pioneers in synthetic biology and computation, Senti is pioneering new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.
Milestones
- 2016 → Founded
- 2018 → Partnered, Series A
- 2022 → IPO; NASDAQ: SNTI
Partner
Vilya is creating a novel class of medicines to treat disease targets inside cells, leveraging its proprietary AI engine to design for drug-like properties and ultimately generate new drug candidates.
Milestones
- 2022 → Founded
- 2023 → Partnered, Series A
Partner
In the News
Menlo Ventures continues scaling focus on tech-enabled bio
July 11, 2023
Riva Health wants to turn your smartphone into a blood pressure monitor
March 17, 2021
This Startup Wants to Take Your Blood Pressure With an iPhone
March 16, 2021
Making wearables matter: Blood pressure monitoring could be the tipping point
July 11, 2019